Key Highlights

  • Lucid Diagnostics (NASDAQ:LUCD) traded at USD 0.45 intraday on November 13, 2026, up 8.14%, with a Market Value of about USD 85.9 million.
  • Medicare now pays a national rate of USD 1,938.01 per EsoGuard test from October 2026, and October test Volume exceeded 1,800.
  • Third quarter Revenue was flat at about USD 1.2 million on 2,871 tests, and cash was USD 18.0 million at September 30, 2026, before a USD 15.0 million preferred stock placement.
  • The company carries a Going Concern warning and has until April 12, 2027 to regain the Nasdaq USD 1.00 minimum bid price.

Medicare Payment Is the Turning Point Management Is Selling

Lucid Diagnostics reported third quarter results and held a Business update call on November 12, 2026, and the central message was reimbursement. Its EsoGuard test, which detects precancerous changes in the oesophagus from a non-invasive cell sample, now has a national Medicare payment rate of USD 1,938.01 per test, effective from October 2026. Until now, low reimbursement has been the main barrier between testing volume and revenue. Management said October test volume exceeded 1,800, a monthly record that compares with 2,871 tests in the whole third quarter. If that pace holds and a meaningful share of tests are paid at the Medicare rate, quarterly revenue could rise well above the current level. Draft guidelines from a leading gastroenterology society also reference the test, which could support wider use by physicians. The shares rose 8.14% to USD 0.45 on November 13 on volume of about 1.44 million shares, below the three-month average of about 5.01 million, so the reaction has been measured.

The Numbers Behind the Optimism

Reported figures remain small. Third quarter revenue was about USD 1.2 million, flat from a year earlier, although nine month revenue rose 22% to about USD 3.9 million. Operating expenses were about USD 13.5 million in the quarter, up 4%, and the adjusted loss was about USD 10.6 million. Over nine months the net loss reached about USD 32.3 million and operating cash burn about USD 38.9 million. Cash stood at USD 18.0 million at September 30, and after the quarter the company raised USD 15.0 million through Series C convertible preferred stock that carries a 20% annual Dividend payable in stock. Convertible notes issued in 2024 were also repriced from USD 1.00 to about USD 0.35 per share. Both steps add to potential dilution. Lucid also pays a monthly management fee of about USD 1.05 million to its majority shareholder, which provides staff and services, and that cost is a meaningful part of its expense base. Commercial insurers are not covered by the Medicare rate, so the mix of payers will also determine how much of each test is actually collected.

Risks Holders Need to Weigh

The company has disclosed substantial doubt about its ability to continue as a going concern, meaning it needs more Capital to fund its plans for the next year. Nasdaq notified it on October 12, 2026 of a bid price deficiency, with a deadline of April 12, 2027, and a reverse split is a possible response. The key test for Lucid Diagnostics (NASDAQ:LUCD) is whether the Medicare rate turns record volume into revenue that narrows losses quickly enough to limit further dilution. Collection rates, commercial payer coverage and the fourth quarter revenue figure will provide the first evidence. Investors should also watch whether the monthly fee to the Majority Shareholder is renegotiated as the business grows.

Where Things Stand

Lucid Diagnostics traded at USD 0.45 on November 13, 2026 after confirming a national Medicare rate of USD 1,938.01 for EsoGuard and record October volume. Revenue is still about USD 1.2 million a quarter, losses are large and a going concern warning applies. Watch fourth quarter revenue, collections and financing.